BISPECIFIC ANTIBODY AND USE THEREOF

Anti-human CD19 antibodies

MALARIA VACCINE AND METHODS FOR PRODUCING SAME

PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1

Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Nucleic acid sequencing using affinity reagents

FRIZZLED5 PROTEIN-BINDING AGENTS

Anti-CD112R compositions and methods

Antibody/T-cell receptor chimeric constructs and uses thereof

Humanized and chimeric monoclonal antibodies to CD47

Compositions and methods for producing a composition

MRNA display antibody library and methods

Highly potent antibodies binding to death receptor 5

MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME

PROTEINS BINDING NKG2D, CD16 AND P-CADHERIN

MULTI-SPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF

Methods for manipulating phagocytosis mediated by CD47

Cancer treatment with an antibody

Therapeutic targeting of non-cellular structures

Anti-O2 antibodies and uses thereof

Monoclonal antibody anti-FGFR4

Antibodies binding to HLA-A2/MAGE-A4

Anti-PD1 antibodies and their use as therapeutics and diagnostics

ANTI-CD37 ANTIBODIES

ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS

Anti-MUC1 antibody

PROTEINS BINDING NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS

Anti-BCMA chimeric antigen receptors

BCMA monoclonal antibody-drug conjugate

Checkpoint inhibitor and a whole cell for use in cancer therapy

CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY

Therapeutic antibodies against ROR-1 protein and methods for use of same

Proteins specific for BAFF and B7RP1 and uses thereof

TARGETING GENE AMPLIFICATION IN CANCER USING TRIPLEX FORMATION AS A THERAPEUTIC STRATEGY

Compositions and methods for the depletion of CD117+ cells

Anti-Jagged2 antibodies and methods of use

PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN

COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS

EGFR and C-met fibronectin type III domain binding molecules

Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection

Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use

Anti PD-1 antibodies

Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation

Combine harvester concave threshing bar

Methods of using bispecific antigen-binding constructs targeting HER2

Human monoclonal antibodies to ganglioside GD2

Therapeutic antibodies and their uses

Humanized, mouse or chimeric anti-CD47 monoclonal antibodies

Monoclonal antibodies and conjugates against prostaglandin F2 receptor inhibitor and uses thereof

Antibodies that bind interleukin-2 and uses thereof

Medical device for administering anti-IL-23 antibodies

Treatment of fibrosis

ANTI-MUC1 ANTIBODY-DRUG CONJUGATE

Anti-STEAP1 antigen-binding protein

Antibodies for treatment of cancer expressing claudin 6

Antibodies specific for CD47, PD-L1, and uses thereof

APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS

COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER

Production of T cell retargeting hetero-dimeric immunoglobulins

Anti-SIRP-alpha antibodies and related methods

B cell maturation antigen binding proteins

Anti-B7-H1 antibodies for treating tumors

Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection

Use of Oncolytic Herpes Simplex Virus, Alone or in Combination with Immune Check-Point Inhibitor, in the Treatment of Cancer

Use of marizomib for the treatment of central nervous system (CNS) cancers

COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS

MDR immunogen

MODULATING ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS

Variant CD3-binding domains and their use in combination therapies for the treatment of disease

ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS

IL-1β neutralizing human monoclonal antibodies

IL-1β neutralizing human monoclonal antibodies

Monoclonal antibody against nerve growth factor, and encoding gene and use thereof

Oxadiazole linkers and use thereof

BI-SPECIFIC ANTIBODIES AND USES THEREOF

Mutant antibodies and conjugation thereof

Compositions and methods for CD20 immunotherapy

Humanized DR4 antibody gene having apoptosis-inducing activity and dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent using same

Anti-CD123 antibodies and conjugates and derivatives thereof

ANTIGEN BINDING PROTEINS WHICH BIND TO THE pMHC HLA-DQ2.5:DQ2.5 PRESENTING A GLIADIN PEPTIDE

AGONISTIC ANTIBODIES THAT BIND CD40

Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof

FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION

Treatment of angiogenesis disorders

The IgM and IgE Heavy Chain Domain 2 as Covalently Linked Homodimerization Modules for the Generation of Fusion Proteins with Dual Specificity

Anti-HER2 antibodies

ANTIBODY FC VARIANTS

Optimized Fc variants

Antibodies to CD40 with enhanced agonist activity

Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR

Antibodies specific to glycosylated PD-1 and methods of use thereof

Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection

MULTISPECIFIC ANTIBODY PRODUCT THAT BINDS TO DIFFERENT ROR1 EPITOPES

METHOD FOR PURIFYING ANTIBODIES

COMBINATION THERAPY FOR CANCER TREATMENT

MULTISPECIFIC BINDING PROTEINS TARGETING CEA

MEDICAMENT COMPRISING ANTI-PHOSPHOLIPASE D4 ANTIBODY

Anti-BCMA antibodies and treatment methods

Anti-MET antibodies and methods of use thereof

MULTISPECIFIC BINDING PROTEINS TARGETING CAIX, ANO1, MESOTHELIN, TROP2, OR CLAUDIN-18.2

PROTEINS BINDING CD33, NKG2D AND CD16

Bispecific antibody construct directed to MUC17 and CD3

Trifunctional T cell-antigen coupler and methods and uses thereof

Chimeric antigen receptors targeting b-cell maturation antigen

METHODS FOR TREATING NETOSIS AND NEUTROPHIL ACTIVATION

ENGINEERED POLYPEPTIDE CONJUGATES AND METHODS FOR MAKING THEREOF USING TRANSGLUTAMINASE

COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF

ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR)

Human monoclonal antibodies against LAG3 and uses thereof

SEPARATION MOIETIES AND METHODS OF USE THEREOF

METHODS AND COMPOSITIONS FOR TH9 CELL MEDIATED CANCER TREATMENT

Constructs specifically recognizing glypican 3 and uses thereof

Heterodimeric antibodies that bind CD3 and tumor antigens

COVALENT MULTI-SPECIFIC ANTIBODIES

Antibodies that specifically bind PD-1 and methods of use

Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof

Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance

Engineered T cell receptors and immune therapy using the same

High Affinity Human Antibodies to Human Angiopoietin-2

CL and/or CH1 mutated antibodies for drug conjugation

PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN

Enhancing the therapeutic activity of an immune checkpoint inhibitor

Chimeric antigen receptors targeting B-cell maturation antigen

Chimeric antigen receptors targeting B-cell maturation antigen

PSMA Targeting Trispecific Proteins and Methods of Use

PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

TRAILR2 CDH17 binding molecules for the treatment of cancer

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

Antibody molecules for cancer treatment

Targeted immunotolerance

Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists

Humanized and chimeric monoclonal antibodies to CD47

Anti-TIGIT antibodies and uses thereof

Anti-CXCL13 antibodies and methods of using the same

ANTIBODY-INTERFERON FUSION PROTEINS FOR ENHANCING ADOPTIVE T CELL THERAPIES FOR THE TREATMENT OF CANCER

Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer

THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS

Humanized antibodies against CD269 (BCMA)

PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds

Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

Anti-GM-CSF antibodies and uses thereof

Anti-angiopoietin-2 antibodies that induce Tie2 activation

Treatment of cancer using GFR alpha-4 chimeric antigen receptor

Bispecific antibody or antibody mixture with common light chains

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Combination of anti-HGFR antibody and HEGFR for the treatment of a tumor and/or metastasis

ANTI-CD47 ANTIBODIES THAT DO NOT CAUSE SIGNIFICANT RED BLOOD CELL AGLLUTINATION

Constructs having a SIRP-alpha domain or variant thereof

CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES

Trispecific and/or trivalent binding proteins

Combination therapies with anti-CD38 antibodies

ANTIBODIES TARGETING, AND OTHER MODULATORS OF, AN IMMUNOGLOBULIN GENE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF

VEGF/DLL4 binding agents and uses thereof

Cell-permeable stapled peptide modules for cellular delivery

ANTIBODIES BINDING TO GPRC5D

Therapeutic antibodies and their uses

Anti-CD25 antibody agents

Antibody variable domains targeting the NKG2D receptor

Anti-PD-L1 antibodies and uses thereof

Anti-CD47 antibodies and uses thereof

NUCLEIC-ACID CONTAINING LIPID NANO-PARTICLE AND USE THEREOF

Treatment of metastatic breast cancer

Bi-Specific Monovalent Diabodies That are Capable of Binding CD123 and CD3, and Uses Thereof

Anti-CD25 for tumour specific cell depletion

Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules

MICA/B ANTIBODIES AND METHODS OF USE

Compositions monovalent for CD28 binding and methods of use

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

Anti-CD38 antibodies for treatment of acute myeloid leukemia

Anti-CD25 for tumour specific cell depletion

Chimeric antigen receptors against multiple HLA-G isoforms

Markers of acute myeloid leukemia stem cells

Anti-TIGIT antibody and use thereof

Cancer treatment combinations

ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER

BISPECIFIC ANTIBODY WITH PROLONGED HALF-LIFE AND ENHANCED ANTI-TUMOR EFFECT

CD20 BINDING MOLECULES AND USES THEREOF

Dual-function antibodies targeting VEGFR2 and VEGFR3

EGFRVIII ANTIBODY AND CONJUGATE, AND PREPARATION METHOD AND USE THEREOF

Antibodies to galectin-3 and methods of use thereof

ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE

Methods of using bispecific CD33 and CD3 binding proteins

METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS

Human anti-semaphorin 4D antibody

Compositions and methods to regulate Renalase in the treatment of cancer

Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy

Binding molecules specific for ASCT2 and uses thereof

IL-1β neutralizing human monoclonal antibodies

Anti-PfRH5 antibodies and antigen-binding fragments thereof

Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma

Cellular immunotherapy compositions and uses thereof

Multifunctional immune cell therapies

STREP-TAG SPECIFIC CHIMERIC RECEPTORS AND USES THEREOF

Anti-siglec-5 antibodies and methods of use thereof

Antibacterial antibody and use thereof

Glycan-Interacting Compounds and Methods of Use

Methods of using monoclonal antibodies targeting epitopes of ASPH

Methods and compositions relating to bispecific anti-CHI3L1 antibody reagents for the treatment of cancer

Anti-CD25 for tumour specific cell depletion

Anti-CD25 for tumour specific cell depletion

Anti-CD25 for tumour specific cell depletion

Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein

Anti-CD25 antibody agents

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

Anti-neurotensin long fragment antibodies and uses thereof

Treatment of cancer using a CD123 chimeric antigen receptor

Multivalent binding molecules

Transgene genetic tags and methods of use

NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER

Human mesothelin chimeric antigen receptors and uses thereof

ANTI CD30 CHIMERIC ANTIGEN RECEPTOR AND ITS USE

Anti-CD25 antibody agents

Fusion Proteins Containing CD48 Antibodies and Cytokines

BISPECIFIC ANTIBODIES TO MOSPD2 AND T CELL- OR NK CELL-SPECIFIC MOLECULES

Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof

Antibodies to surface determinants

Articles and methods directed to personalized therapy of cancer

Dimeric antigen receptors

Antibodies against OX-40 and uses thereof

Agents for Treatment of Claudin Expressing Cancer Diseases

Anti-claudin 18.2 antibodies and uses thereof

COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF

Anti-annexin A2 monoclonal antibodies

Multispecific antibodies

TGF-β3 specific antibodies and methods and uses thereof

Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer

Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate

HUMAN MONOCLONAL ANTI-PD-L1 ANTIBODIES AND METHODS OF USE

Antibody

Anti-C10orf54 antibodies and uses thereof

BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES

Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Diagnosis and therapy of cancer involving cancer stem cells

Antibodies to L-type voltage gated channels and related methods

Monoclonal antibodies against Claudin-18 for treatment of cancer

Cell culture medium

Methods for determining DPP3 and therapeutic methods

SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES

Anti-jagged antibodies and methods of use

Agonistic antibodies that bind human CD40 and uses thereof

Humanized antibodies for CD3

Multispecific antibodies that target HIV GP120 and CD3

Anti-CKAP4 monoclonal antibody

Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof

COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS

Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

Methods for depleting or inhibiting the migration of regulatory T-cells in early or late stages of cancer

Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies

Bispecific antigen binding proteins

COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD2+ CELLS

Methods for expansion or depletion of T-regulatory cells

ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER

Compositions and methods for TCR reprogramming using fusion proteins

Anti-presenilin antibody for use in the prevention and/or treatment of cancer

Anti-CD133 monoclonal antibodies and related compositions and methods

Anti-IL-6/IL-6R antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

CARS AND BISPECIFIC ANTIBODIES FOR TREATMENT OF MANTLE CELL LYMPHOMA

Chimeric antigen receptors comprising a human transferrin epitope sequence

Human antibodies binding to ROR2

Bispecific molecules comprising an HIV-1 envelope targeting arm

Chimeric antigen receptor specific for BDCA2 antigen

Antibodies specific for claudin 6 (CLDN6)

MODULATION OF T CELLS WITH BISPECIFIC ANTIBODIES AND FC FUSIONS

ANTI-ROR1 ANTIBODY AND CONJUGATES THEREOF

Specific sites for modifying antibodies to make immunoconjugates

Anti-CD73 antibodies and uses thereof

Monoclonal antibodies that bind TRBV9 and methods for using same for inhibiting the T cell receptor for treatment

Antibody constructs for DLL3 and CD3

Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor

Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

ANTI-PD-1 ANTIBODIES AND THEIR USES

Compositions and methods for the treatment of immune related diseases

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

Therapeutic antibodies against ROR-1 protein and methods for use of same

Chimeric antigen receptors targeted to PSCA

ANTI-GPC-1 ANTIBODY

Anti-LY6H antibodies and antibody drug conjugates

Carrier-binding agent compositions and methods of making and using the same

Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

Anti-CD3 antibodies and methods of use

Anti-CD3 antibodies and methods of use

TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE

Anti-ErbB3 antibodies

Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use

Antibodies against human and canine IL-13RA2

ROR1 antibody compositions and related methods

Anti-FAM19A5 antibodies and uses thereof